1-2 of 2
Silvia L. Locatelli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530

Free
Silvia L. Locatelli, Giuseppa Careddu, Simone Serio, Francesca M. Consonni, Akihiro Maeda, Srikant Viswanadha, Swaroop Vakkalanka, Luca Castagna, Armando Santoro, Paola Allavena, Antonio Sica, Carmelo Carlo-Stella
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 1098–1112.
https://doi.org/10.1158/1078-0432.CCR-18-1133
Published: 01 February 2019
View articletitled, Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530
Open the PDF for Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530 in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases

Free
Anna Guidetti, Carmelo Carlo-Stella, Silvia L. Locatelli, Walter Malorni, Roberta Mortarini, Simonetta Viviani, Domenico Russo, Alfonso Marchianò, Roberto Sorasio, Anna Dodero, Lucia Farina, Laura Giordano, Massimo Di Nicola, Andrea Anichini, Paolo Corradini, Alessandro M. Gianni
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5641–5651.
https://doi.org/10.1158/1078-0432.CCR-14-0770
Published: 13 November 2014
View articletitled, Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases
Open the PDF for Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases in another window
Includes: Supplementary data